Home / Wiki / G / Gene Editing

Gene Editing

Investment and Capital MarketsUpdated 16 Nov 2026

Gene editing is a group of technologies that make deliberate, targeted changes to the DNA of living cells. The best known is CRISPR-Cas9, which uses a guide molecule to direct a cutting enzyme to a chosen site in the genome. Its developers, Emmanuelle Charpentier and Jennifer Doudna, received the Nobel Prize in Chemistry in 2020. Newer methods, called base editing and prime editing, alter single DNA letters without cutting both strands. Editing may be done on cells removed from the patient and later returned, or inside the body, which is in vivo gene editing.

The first CRISPR-based medicine, a treatment for sickle cell disease, was approved in 2023. In thematic investing, gene editing is grouped with genomics as a field in which a single treatment might offer a functional cure. Companies in the field are mostly loss-making, and their value depends on trial results, regulatory decisions, patents and the price that health systems will pay.

Last updated 16 Nov 2026